PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20703083-6	2010	Treatment of Tyr-HRas:Cdk4(R24C/R24C) mice with the carcinogen, DMBA/TPA resulted in a further increase in the number of nevi and melanomas developed when compared with Tyr-HRas:Cdk4(+/+) mice.	Tyrosine	13-16	Harvey rat sarcoma virus oncogene	Mus musculus	17-21	
20703083-6	2010	Treatment of Tyr-HRas:Cdk4(R24C/R24C) mice with the carcinogen, DMBA/TPA resulted in a further increase in the number of nevi and melanomas developed when compared with Tyr-HRas:Cdk4(+/+) mice.	Tyrosine	13-16	Harvey rat sarcoma virus oncogene	Mus musculus	173-177	
20703083-6	2010	Treatment of Tyr-HRas:Cdk4(R24C/R24C) mice with the carcinogen, DMBA/TPA resulted in a further increase in the number of nevi and melanomas developed when compared with Tyr-HRas:Cdk4(+/+) mice.	Tyrosine	169-172	Harvey rat sarcoma virus oncogene	Mus musculus	17-21	
20703083-7	2010	In summary, in Tyr-HRas:Cdk4(R24C/R24C) mice, we observed that activated CDK4 cooperates with the oncogenic HRAS(G12V) protein to increase the susceptibility of melanoma development in vivo.	Tyrosine	15-18	Harvey rat sarcoma virus oncogene	Mus musculus	19-23	
20703083-7	2010	In summary, in Tyr-HRas:Cdk4(R24C/R24C) mice, we observed that activated CDK4 cooperates with the oncogenic HRAS(G12V) protein to increase the susceptibility of melanoma development in vivo.	Tyrosine	15-18	Harvey rat sarcoma virus oncogene	Mus musculus	108-112